Alembic Pharma Slashes the Price of Tofastar by 50% for Benefit of Rheumatoid Arthritis Patients - Video

Published On 2024-03-04T11:55:00+05:30 | Updated On 17 Aug 2024 11:27 AM IST

Overview

One of the leading pharmaceutical majors in India, Alembic Pharmaceuticals Limited, has recently announced a 50% reduction in the prices of its Tofacitinib brand, Tofastar.

Tofastar 5mg tablets contain Tofacitinib Citrate 5mg; and is approved by DCGI for treatment of patients with moderately to severely active rheumatoid arthritis (RA) and psoriatic arthritis (PsA). It helps to reduce pain, tenderness, and swelling in the affected joints.

In an endeavor to make Tofacitinib treatment more affordable, Alembic is now introducing Tofastar 5 mg tablets at Rs. 19 per tablet, which is almost a thousand Rupees for 4 weeks of therapy.

Tofacitinib citrate contained in Tofastar is the citrate salt form of tofacitinib, an orally bioavailable inhibitor of Janus Kinase (JAK). Tofacitinib possesses immuno-modulatory and anti-inflammatory activities.

Several international guidelines including the Asia Pacific League of Associations for Rheumatology (APLAR) recommend consideration of JAK inhibitors in appropriate Rheumatoid Arthritis patients. The use of JAK inhibitors may be applicable in patients with high levels of rheumatoid factor (RF) and anticitrullinated protein antibody (ACPA), high disease activity, early joint damage, and failure of conventional synthetic disease-modifying antirheumatic drugs (csDMARDs), after risk assessment.

Mr. Vimal Wahi, VP –Sales & Marketing, from Alembic, said, “Alembic remains committed to alleviating the challenges faced by millions of rheumatoid arthritis patients in seeking access to essential medications. With the price drop of Tofastar, we aim to ensure that every rheumatoid arthritis patient can afford the highest quality medicine at a patient-friendly price. We will also be launching Tofacitinib extended release 11 mg as Tofastar OD for patient compliance very soon”.

References:

Smolen JS, et al EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update Annals of the Rheumatic Diseases 2020;79:685-699.
Fraenkel L, et.al. 2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Rheumatol. 2021 Jul;73(7):1108-1123. doi: 10.1002/art.41752. Epub 2021 Jun 8. PMID: 34101376.
Lau CS, et. al 2018 update of the APLAR recommendations for treatment of rheumatoid arthritis. Int J Rheum Dis. 2019 Mar;22(3):357-375. doi: 10.1111/1756-185X.13513. Epub 2019 Feb 27. PMID: 30809944.

Disclaimer: This post has been published under MD Brand Connect Initiative and is sponsored by Alembic Pharmaceuticals Limited

Speakers

Dr. Nandita Mohan

BDS, MDS( Pedodontics and Preventive Dentistry)

Dr. Nandita Mohan is a practicing pediatric dentist with more than 5 years of clinical work experience. Along with this, she is equally interested in keeping herself up to date about the latest developments in the field of medicine and dentistry which is the driving force for her to be in association with Medical Dialogues. She also has her name attached with many publications; both national and international. She has pursued her BDS from Rajiv Gandhi University of Health Sciences, Bangalore and later went to enter her dream specialty (MDS) in the Department of Pedodontics and Preventive Dentistry from Pt. B.D. Sharma University of Health Sciences. Through all the years of experience, her core interest in learning something new has never stopped. She can be contacted at editorial@medicaldialogues.in. Contact no. 011-43720751

MD Brand Connect

Dr. Kamal Kant Kohli

Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751